Remove 2007 Remove Clinical Trials Remove Terpenes
article thumbnail

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. Fig 1: Sucralose (In Study).

article thumbnail

Dr. Andrew Weil on Cannabis and Integrative Medicine

Project CBD

He is the author of several bestselling books, including Spontaneous Healing (1995), Eating Well for Optimum Health (2000), and Healthy Aging (2007). We rate levels of evidence, and a high level may be a controlled randomized clinical trial (RCT), but there are also observational studies. How do you standardize for that?

Medicine 301
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Paper: The transition of cannabis into the mainstream of Australian healthcare: framings in professional medical publications

Cannabis Law Report

Research into the plant’s chemical compounds has also revealed a rich array of terpenes and flavonoids that may also account for the plant’s therapeutic effects (Kotsirilos and McGregor 2021 ). It is unclear whether doctors are feeling completely reassured by laboratory and clinical trial research into medicinal cannabis.

article thumbnail

ElleVet Sciences Publishes Safety Study On CBD For Animals

Cannabis Law Report

Wakshlag is well-known in the veterinary medicine community as the first doctor to conduct an efficacy study in dogs in a clinical trial at Cornell using ElleVet CBD/CBDA on dogs with multi-joint discomfort. The clinical trial results confirmed more than 80% of dogs showed significant or dramatic improvement.

Safety 45
article thumbnail

Israel’s Tikun Olam Making Moves in the U.S. and Canada

Freedom Leaf

Tikun Olam , which was founded in 2007, controls nearly 40% of the Israeli medical-marijuana market. We’re also continuing to do some other clinical trials in Israel, specifically with our strains.” We’ve been able to do this for 15 years, which provided us with the ability to do more clinical trials and research.